Here are five points:
1. The company aims to raise up to $150 million through the IPO.
2. The company intends to use the funds to “pay off promissory notes and other debt that total $60 million among other things,” according to the report.
3. Bioventus, a spin-off of Smith & Nephew formed in 2012, develops orthobiologic solutions for bone fusion and osteoarthritis.
4. The company’s full-year revenue increased from $242.9 million in 2014 to $253.7 million in 2015; however, its net loss in 2015 totaled $34.1 million.
5. If Bioventus moves forward with the IPO, it will trade under the ticker symbol “BIOV” on Nasdaq.
More articles on devices:
Amendia, Benvenue Medical, Zimmer Biomet & more: 15 key notes
Amendia names Chris Fair CEO: 4 points
Trusting a robot — Dr. Juan Torres-Reveron on performing 1st US ROSA Spine surgery
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
